Biomed 101

Biomed 101 is an experimental drug studied for its potential to reduce the side effects of administered Interleukin 2.

IL-2 is a signaling molecule in the immune system, and has been tested in many clinical trials as an immunotherapy for the treatment of cancers, chronic viral infections and as adjuvants for vaccines. Biomed 101 has been shown not to affect interleukin-2 antitumor activity, and may alleviate IL-2's side effects such as IL-2-mediated hypoxia.